GSK plc

LSE:GSK Stock Report

Market Cap: UK£53.9b

GSK Past Earnings Performance

Past criteria checks 0/6

GSK's earnings have been declining at an average annual rate of -5.2%, while the Pharmaceuticals industry saw earnings declining at 5.2% annually. Revenues have been declining at an average rate of 1.8% per year. GSK's return on equity is 21.2%, and it has net margins of 8%.

Key information

-5.2%

Earnings growth rate

-5.8%

EPS growth rate

Pharmaceuticals Industry Growth14.1%
Revenue growth rate-1.8%
Return on equity21.2%
Net Margin8.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

GSK's (LON:GSK) Conservative Accounting Might Explain Soft Earnings

Nov 06
GSK's (LON:GSK) Conservative Accounting Might Explain Soft Earnings

Recent updates

Does GSK (LON:GSK) Have A Healthy Balance Sheet?

Dec 01
Does GSK (LON:GSK) Have A Healthy Balance Sheet?

GSK's (LON:GSK) Conservative Accounting Might Explain Soft Earnings

Nov 06
GSK's (LON:GSK) Conservative Accounting Might Explain Soft Earnings

GSK plc (LON:GSK) Not Flying Under The Radar

Nov 02
GSK plc (LON:GSK) Not Flying Under The Radar

GSK (LON:GSK) Is Paying Out A Dividend Of £0.15

Nov 02
GSK (LON:GSK) Is Paying Out A Dividend Of £0.15

Does GSK (LON:GSK) Have A Healthy Balance Sheet?

Sep 01
Does GSK (LON:GSK) Have A Healthy Balance Sheet?

GSK (LON:GSK) Is Paying Out A Dividend Of £0.15

Aug 05
GSK (LON:GSK) Is Paying Out A Dividend Of £0.15

GSK (LON:GSK) Will Pay A Dividend Of £0.15

May 05
GSK (LON:GSK) Will Pay A Dividend Of £0.15

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

May 02
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

These 4 Measures Indicate That GSK (LON:GSK) Is Using Debt Reasonably Well

Apr 19
These 4 Measures Indicate That GSK (LON:GSK) Is Using Debt Reasonably Well

Revenue & Expenses Breakdown

How GSK makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

LSE:GSK Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2431,3112,51110,8396,042
30 Jun 2431,4464,0339,2846,049
31 Mar 2430,7404,4849,0705,956
31 Dec 2330,3284,9289,1565,823
30 Sep 2329,6526,0788,9655,580
30 Jun 2329,3345,3738,7675,436
31 Mar 2329,0854,4558,4605,282
31 Dec 2229,3244,4618,1795,153
30 Sep 2229,0243,3877,8034,905
30 Jun 2227,8223,5057,4294,741
31 Mar 2226,7314,0137,1044,691
31 Dec 2124,6963,3166,7844,627
30 Sep 2126,3593,5677,4364,640
30 Jun 2128,3783,9348,2854,566
31 Mar 2130,1644,9839,1764,622
31 Dec 2024,3544,8737,0414,397
30 Sep 2034,2596,37110,7194,537
30 Jun 2034,9986,67911,0854,648
31 Mar 2035,1835,38010,9934,519
31 Dec 1933,7544,64510,9624,405
30 Sep 1933,0524,56110,1034,266
30 Jun 1931,7594,4279,5754,065
31 Mar 1931,2603,9049,4883,887
31 Dec 1830,8213,6239,5003,799
30 Sep 1830,2631,8629,2343,755
30 Jun 1830,0141,6569,1853,696
31 Mar 1830,0241,0359,1433,890
31 Dec 1730,1861,5329,4243,925
30 Sep 1730,1332,3359,3033,886
30 Jun 1729,8321,9319,2603,863
31 Mar 1729,0441,6769,0173,604
31 Dec 1627,8899128,8523,550
30 Sep 1626,5893018,5533,370
30 Jun 1625,174318,0253,226
31 Mar 1624,5306158,0973,163
31 Dec 1523,9238,4229,2323,560
30 Sep 1523,8239,8097,8103,218
30 Jun 1523,3429,6727,4253,227
31 Mar 1523,01510,1777,2613,258
31 Dec 1423,0062,7568,2463,450
30 Sep 1423,7264,1847,2093,333
30 Jun 1424,5904,7527,6733,359
31 Mar 1425,6475,1437,8203,478
31 Dec 1326,5055,4368,4803,923

Quality Earnings: GSK has a large one-off loss of £3.0B impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: GSK's current net profit margins (8%) are lower than last year (20.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: GSK's earnings have declined by 5.2% per year over the past 5 years.

Accelerating Growth: GSK's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: GSK had negative earnings growth (-58.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9.5%).

Return on Equity

High ROE: Whilst GSK's Return on Equity (21.17%) is high, this metric is skewed due to their high level of debt.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 00:25
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

GSK plc is covered by 63 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kamla SinghAlphaValue
John EadeArgus Research Company
Odile RundquistBaader Helvea Equity Research